Recent corporate updates for Verastem Oncology highlight positive net product revenue growth from its commercial co-pack offerings, ongoing clinical trial progress evaluating targeted RAF/MEK and KRAS pathway inhibitors, and strategic updates shared during quarterly financial earnings calls.